Subscribe
Share
Share
Embed
Welcome to EP Edge Journal Watch, where cardiac electrophysiology meets evidence, precision, and perspective.
Hosted by Dr. Niraj Sharma, this weekly podcast distills high-impact cardiovascular and Cardiac Electrophysiology and arrhythmia research into clear, clinically meaningful insights. Each episode goes beyond headlines and abstracts to uncover what new studies actually mean for patient care, decision-making, and the future of electrophysiology.
What EP Edge Journal Watch stands for:
Evidence-based practice
Precision electrophysiology, arrhythmias analysis
A forward-thinking, edge-driven approach to how we interpret and apply data in real-world clinical settings.
Whether you’re an electrophysiologist, cardiologist, researcher, trainee, or allied health professional, EP Edge Journal Watch brings you the signal not the noise. Expect sharp summaries, thoughtful commentary, and practical takeaways designed for the busy clinician who wants to stay ahead of the curve
This program is for educational purposes only and reflects independent editorial commentary. It is not medical advice and should not replace clinical judgment or review of primary sources and guidelines.
Niraj Sharma:Hi everyone, I'm Doctor. Sharma and welcome to this special edition of EP Edge Journal Watch. I'm genuinely excited to bring you this episode because we're coming to you with breaking science from the European Society of Cardiology Congress in Munich 2026. This is one of those meetings where you can feel the field shifting in real time. Today we are going to focus first on the major electrophysiology stories and then we will move into a rapid fire section covering the new heart failure guidelines, the fifth universal definition of myocardial infarction, nicotine and cardiovascular disease, and the AI mammogram signal.
Niraj Sharma:What makes this meeting so interesting is that several of these presentations challenge old thresholds and old ways of thinking. In other words, this is not just about new data, it's about new frameworks. Let's begin with SINGLE AF, led by Daehoon Kim and colleagues, presented at ESC and published in August 2026 in the New England Journal of Medicine. This trial addressed a question that comes up constantly in clinical practice: what do we do with the patient who has atrial fibrillation but sits in that uncomfortable middle zone of stroke risk? Not high enough to make anticoagulation an automatic decision, but not so low risk that we can confidently walk away from it either.
Niraj Sharma:For years, this has been a grey area. We have had registry data, observational analyses and guideline language saying anticoagulation is reasonable in selected patients with intermediate risk. But we have not had randomized evidence directly asking whether a direct oral anticoagulant is actually better than no anticoagulation in this population. That is why single AF matters. The intent of the study was very practical.
Niraj Sharma:Can anticoagulation improve net clinical outcomes in AF patients with intermediate stroke risk, and can it do so without simply trading stroke prevention for excess bleeding? Methodologically, this was a multicenter randomized trial conducted in South Korea. Patients with atrial fibrillation and intermediate stroke risk were assigned either to a direct oral anticoagulant strategy or to no routine anticoagulation. The endpoint was clinically meaningful and balanced, combining thromboembolic outcomes, bleeding, and cardiovascular death. So the trial was not asking only Does anticoagulation reduce stroke?
Niraj Sharma:It was asking the better question Does anticoagulation improve the overall clinical balance? And the answer, at least within this study population, was yes. The direct oral anticoagulant strategy reduced the net clinical endpoint compared with no anticoagulation. The major story was fewer ischemic events without a clear penalty in major bleeding. Now the event rates were low, and that's important.
Niraj Sharma:This was not a trial with huge numbers of events driving a dramatic conclusion. In fact, the very low event burden is part of how we should interpret the findings. Still, randomized evidence in this space is a big deal. Statistically, the hazard ratio favored the direct oral anticoagulant arm, suggesting a meaningful relative reduction in the primary outcome. But when you hear a relative risk reduction, I want you to immediately think about the absolute numbers.
Niraj Sharma:The absolute benefit was modest. That means this is not a story of universal anticoagulation for everyone in the gray zone. It is a story of stronger evidence supporting anticoagulation for the right patient in the gray zone. If you'd like the full statistical breakdown including hazard ratios, confidence intervals, and endpoint definitions, see the latest issue of EP Edge Journal Watch. My EP Edge take is this: single AF strengthens the case for direct oral anticoagulant therapy in patients with intermediate stroke risk, especially when bleeding risk is low and life expectancy is substantial, but it does not eliminate individualized decision making.
Niraj Sharma:This remains a shared decision conversation. Next, we move to what may be the most provocative EP story from Munich, the CMR GUIDE trial. Let's turn now to CMR GUIDE, led by Joseph B. Silvanayagam et al, presented at ESC and published in August 2026 in JAMA. This study goes right at one of the most entrenched thresholds in electrophysiology, the idea that an ejection fraction of 35% is the major dividing line for primary prevention ICD therapy.
Niraj Sharma:Now we all know where that threshold comes from. It comes from landmark trials that shape guideline based device therapy. But we also know something else. Sudden cardiac death does not occur only in people with severely reduced ejection fraction. An ejection fraction, while useful, is really a marker of ventricular function, not a direct measure of arrhythmic substrate.
Niraj Sharma:That is exactly where cardiac MRI enters the conversation. Late gadolinium enhancement identifies myocardial scar. Scar is not just a structural finding. In many patients, scar is the substrate for ventricular arrhythmia. Over the years, observational studies have strongly suggested that scar predicts arrhythmic risk above and beyond ejection fraction.
Niraj Sharma:But the missing piece has been randomized evidence. Does identifying scar actually help us select patients who benefit from ICD therapy? That is the question CMR GUIDE tried to answer. The investigators enrolled patients with ischemic or nonischemic cardiomyopathy, an ejection fraction in the thirty six-fifty percent range, and CMR defined myocardial scar. These were patients who did not meet the classic low EF ICD indication, but who clearly had potentially important arrhythmic substrate.
Niraj Sharma:Patients were randomized either to a primary prevention ICD or to an implantable loop recorder strategy. I want to pause here because the design itself tells a story. This was not just a study of whether scar predicts outcomes, we already had quite a bit of data suggesting that. This was a study asking a much more clinically useful question. If you identify scar in these moderately reduced EF patients and then act on that information with ICD therapy, do you improve meaningful outcomes?
Niraj Sharma:The primary endpoint combined sudden cardiac death and hemodynamically significant ventricular arrhythmia and on that primary endpoint the trial was neutral. That is the first and most important fact. CMR GUIDE was not a conventionally positive primary endpoint trial. We have to be disciplined about that. But this is where the study becomes fascinating.
Niraj Sharma:Although the primary endpoint was neutral, sudden cardiac death itself was lower in the ICD group. In addition, the most striking signal appeared in younger patients, especially those 70. So even though the headline says neutral primary endpoint, the underlying biology and the secondary signals suggest there may be a subset of scar positive patients with LVEF above thirty five percent who do derive clinically meaningful benefit from an ICD, and that creates the real tension in interpretation. If the primary endpoint is neutral, how seriously do we take the sudden death signal? If the sudden death signal is real, are we asking the wrong question by relying so heavily on EF alone?
Niraj Sharma:That's exactly why this trial has generated so much discussion. So what do we make of CMR GUIDE statistically and clinically? First, let's be very clear. The study was underpowered relative to its original aspirations. Fewer events occurred than expected.
Niraj Sharma:That matters because when a trial has fewer events, it becomes harder to show a statistically robust difference even if a real clinical signal is present. The primary endpoint again was neutral. Statistically, that means the trial did not prove a clear overall advantage for ICD therapy on its pre specified main outcome. But the sudden cardiac death reduction is not something we can simply ignore. The hazard ratio for sudden cardiac death favored the ICD arm quite strongly.
Niraj Sharma:In plain language that suggests ICD therapy may have prevented fatal arrhythmic events in this scar positive population. There is also an important nuance in the endpoint itself. As Sana Al Qade points out in the accompanying editorial, also published in August 2026 in JAMA, an ICD does not prevent ventricular arrhythmias from occurring, it prevents them from becoming fatal. So if the device rescues a patient from an otherwise fatal ventricular arrhythmia but that arrhythmia still counts in the composite endpoint, you can dilute the very effect the ICD is designed to produce. That is one of the reasons this trial is so thought provoking.
Niraj Sharma:The age interaction is also important. The signal appeared strongest in patients younger than 70. Now, subgroup findings always deserve caution. They can generate insight, but they should not instantly change guidelines. Still, this one makes physiologic sense.
Niraj Sharma:Younger patients generally have less competing nonarrhythmic mortality, so preventing sudden arrhythmic death is more likely to translate into net benefit. That is also conceptually consistent with what we saw years ago in Danish. My EP Edge take is this: CMR guide does not tell us to implant ICDs in every patient with LVEF thirty six-fifty percent and scar. It does not replace current guideline criteria, but it does challenge the adequacy of EF as the dominant arbiter of risk. Scar matters, age matters, competing mortality matters, and the future of sudden death prevention is likely to be based on phenotype, not a single cut off.
Niraj Sharma:In practice what should you do today? I think CMR becomes a more meaningful part of the risk conversation, especially in the younger patient with moderate LV dysfunction and substantial scar burden who feels too high risk to ignore but does not formally cross the traditional ICD threshold. That is not the same as saying the evidence is definitive. It means the evidence is becoming harder to dismiss. If you want the more granular numbers including the primary endpoint event rates, the sudden cardiac death breakdown, and the age subgroup statistics, I'd strongly point you to the full EP Edge Journal Watch newsletter.
Niraj Sharma:From there the conversation broadens, because the very same ESC meeting that gave us CMR also gave us a major redefinition of heart failure. Let's move now to the 2026 ESC Heart Failure Guidelines, led by Lars Kuber, Mariana Adamo and colleagues published in August 2026 in the European Heart Journal. This is not a trial of course, but it is absolutely major breaking news from Munich. The headline change is simple but very important: Heart failure mildly reduced EF is gone. The traditional midrange category has been eliminated, and the classification has been simplified so that heart failure with reduced ejection fraction now includes patients with EF below 50%, while preserved EF begins at 50% and above.
Niraj Sharma:Why does that matter? Because the prior mid range zone often created ambiguity. These were patients who seemed biologically and therapeutically closer to reduced EF heart failure but were stuck in a somewhat awkward middle category. The new framework recognizes that this was not a particularly useful separation. The guidelines also moved toward a stage A through D continuum and reorganized therapy into foundational, additional and guideline directed interventional therapies.
Niraj Sharma:That may sound like semantics, but it actually reflects a shift in how we think about the disease. Prevention, progression and intervention are now more clearly integrated. The EP relevance is immediate. We need to be very careful not to confuse a change in disease classification with a change in device indication. Just because a patient with EF forty two percent now sits under a broadened heart failure reduced EF framework does not mean that patient suddenly has a guideline supported class I ICD or CRT indication.
Niraj Sharma:Those are different evidence streams. My take is that these guidelines set the stage for future device debates. They don't settle them. In fact, they make CMR GUIDE more timely. If the HF world is moving beyond some old EF categories, EP may also have to rethink whether a single EF threshold should dominate sudden death prevention.
Niraj Sharma:Now let's pivot to another major document from Munich, the fifth universal definition of myocardial infarction led by Nicholas Mills, L. Kristin Newby, Sarah Zeeman and colleagues also published in August 2026 in the European Heart Journal with simultaneous co publication in other journals. This update addresses a very real clinical problem. The old Type I, Type II, Type IV, Type V language was widely used but often poorly understood by patients, inconsistently applied by clinicians, and at times disconnected from the biology we were trying to describe. The new system replaces that numeric scheme with a more intuitive pathophysiologic framework: primary MI, secondary MI, and procedure related MI.
Niraj Sharma:Why is that especially relevant for electrophysiology? Because we all see patients with rapid atrial fibrillation, elevated high sensitivity troponin, and no clear evidence of acute coronary plaque rupture. Too often, that reflexively got labeled as type II MI. The new definition forces us to be more precise. Troponin elevation alone is not enough.
Niraj Sharma:You still need evidence that the myocardial injury is ischemic in nature. That may sound subtle, but clinically it is very useful. It should improve documentation, coding, patient communication and frankly thinking. It also reduces the risk of overcalling MI when what we really have is myocardial injury in the setting of tachyarrhythmia. More detail on that in the newsletter but the big message is clarity.
Niraj Sharma:Let's move into two other important stories from this special ESC edition: Nicotine and cardiovascular disease and the AI mammogram signal. First, the nicotine paper. This was led by Thomas Munsell and colleagues, published in August 2026 in Nature Reviews Cardiology. The reason this review matters is that public conversation around nicotine products is often far too binary. People either talk as if all products are equally dangerous or as if non combustible products are basically harmless.
Niraj Sharma:Neither position is quite right. The intent of this review was to synthesize mechanistic and clinical evidence across the spectrum of nicotine delivery systems, from combustible cigarettes to heated tobacco, e cigarettes and oral nicotine products. The major message is that harm exists on a continuum. Removing combustion reduces harm but does not eliminate cardiovascular toxicity. Why is that relevant to us in electrophysiology?
Niraj Sharma:Because nicotine has biologic effects that matter for rhythm. Sympathetic activation, hemodynamic stress, oxidative stress, endothelial dysfunction, and prothrombotic signaling all create a cardiovascular environment that is far from electrically neutral. So the practical EP take is simple: ask in more detail about nicotine use and vaping. Don't just ask Do you smoke? Ask what product, how often, for how long, and whether there has been recent change.
Niraj Sharma:The statistics here are not about one randomized endpoint. This is a synthesis paper, not a superiority trial. So what the evidence means is not one product equals x percent more risk. Rather, it means the mechanistic and emerging clinical data point consistently in the same direction. Reduced harm is not no harm.
Niraj Sharma:Now to one of the more futuristic stories from Munich, the AI mammogram signal presented by Vianna Copeland and colleagues at ESC in August 2026. This study asked a fascinating question: can routine mammographic imaging contain information that helps identify cardiovascular disease? The rationale is actually very clever. Millions of women undergo mammography. If those same images carry detectable cardiovascular signals, then screening infrastructure already in place for one purpose could potentially offer added value for another.
Niraj Sharma:The investigators used AI to analyze a large number of mammograms and found signals associated with hypertension, ischemic heart disease, and stroke. The reported performance metrics, including area under the curve values, were intriguing, especially for stroke. But here is the important statistical translation: Good discrimination does not automatically equal clinical usefulness. Before this can be used in practice, it needs external validation, calibration, prospective assessment, and a clearer understanding of false positives and downstream consequences. My take is that this is a very exciting proof of concept, but not yet a screening tool.
Niraj Sharma:It reminds us that modern imaging may contain more information than we routinely extract from it, and that broader concept may end up being more important than this single study. If you want the exact cohort size and performance figures, they're all laid out in EP Edge Journal Watch. So let's bring this all together. What is the overarching message from this ESC Munich twenty twenty six Special Edition? For me, it is that cardiovascular medicine is moving away from rigid categories and towards smarter phenotyping.
Niraj Sharma:In single AF, Daehoon Kim and colleagues showed that the anticoagulation gray zone in atrial fibrillation now has randomized evidence behind it, not enough to end individualized care, but enough to strengthen the case for direct oral anticoagulants in selected intermediate risk patients. In CMR GUIDE, Joseph Selvanayagam et al. Challenged the idea that EF alone should dominate ICD decision making. The primary endpoint was neutral, but the sudden cardiac death and age signals keep the debate very much alive, especially in younger scar positive patients. The twenty twenty six ESC Heart Failure Guidelines from Lars Kuber, Mariana Adamo, and colleagues in the European Heart Journal redefine the heart failure landscape and make it clear that older EF compartments are being reconsidered.
Niraj Sharma:That has real implications for how future device discussions may evolve. The fifth universal definition of MI, led by Nicholas Mills and colleagues also in the European Heart Journal, brings much needed clarity to myocardial injury versus infarction, and should be especially useful in EP settings where troponin elevation during tachyarrhythmia can be over interpreted. The nicotine review by Thomas Munsell et al. In Nature Reviews Cardiology reminds us that reduced harm does not mean harmless, and the AI mammogram work from Vianna Copeland et al. Hints at a future where routinely acquired images may reveal much more cardiovascular information than we currently recognize.
Niraj Sharma:If I had to summarize this entire special edition in one line, it would be this: stroke risk is not binary, sudden death risk is not binary, and cardiovascular medicine is steadily moving toward more nuanced, substrate based, phenotype based decision making. If you want the deeper statistical analysis, the references, and all the graphics, please head over to the LinkedIn newsletter EP Edge Journal Watch as well as Substack at epedge.substack.com. And a reminder that our EP Edge website, epedge.org is coming soon. Questions, suggestions or concerns, email us at epedge. Castgmail dot com.
Niraj Sharma:Thanks so much for listening. I appreciate you spending this time with EP Edge. Bye for now, take care. I'll see you in the next episode.